Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)

Launched by UNIVERSITY HOSPITAL, BORDEAUX · Jan 30, 2024

Keywords

ClinConnect Summary

This clinical trial, called TIL-GVHD, is studying a condition known as Chronic Graft Versus Host Disease (cGVHD), which can occur after a type of cancer treatment called allogeneic stem cell transplantation. In cGVHD, the new immune cells from the donor can attack the recipient's body, leading to various health issues. Researchers want to better understand the immune system's role in this condition, especially how certain immune cells work together. They believe that looking closely at the tissues affected by cGVHD may help identify important immune players and lead to new treatments.

To participate in this trial, you must be at least 18 years old and have received an allogeneic stem cell transplant. You should either be experiencing cGVHD for the first time or have a history of it that is currently being managed with a low dose of steroids. Participants will need to sign an informed consent form and have health coverage. If you join, you can expect to undergo some tests to help researchers learn more about the disease, which may ultimately improve care for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient \> 18 yo ;
• • Having undergone an allogeneic stem cell tranplant ;
• • 2 groups of patients will be eligible
• • showing evidence of primary cGVHD or occuring after Donor Lymphocyte Infusion
• • in the case of first occurrence of cGVHD, in the absence of any new systemic therapy ;
• • in the case of recurrent cGVHD, steroid dose has to be below 15mg/day of Prednisone ;
• • Having read, understood and signed an informed consent of the study;
• • With social security affiliation;
• Exclusion Criteria:
• • Patient below 18 yo or unable to give consent ;
• • Systemic therapy using steroids over 15mg/d of Prednisone ; and/or the use of other systemic agent introduced in the last month ;
• • Haemorrhagic risk of biopsy anticipated ;
• • Absence of patient agreement for the study